Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA
Background The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated. Methods A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed....
Gespeichert in:
| Veröffentlicht in: | International journal of clinical oncology 2020-04, Vol.25 (4), p.622-632 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 632 |
|---|---|
| container_issue | 4 |
| container_start_page | 622 |
| container_title | International journal of clinical oncology |
| container_volume | 25 |
| creator | Ushigome, Mitsunori Shimada, Hideaki Miura, Yasuyuki Yoshida, Kimihiko Kaneko, Tomonori Koda, Takamaru Nagashima, Yasuo Suzuki, Takayuki Kagami, Satoru Funahashi, Kimihiko |
| description | Background
The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.
Methods
A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.
Results
Although preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.
Conclusions
Postoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator. |
| doi_str_mv | 10.1007/s10147-019-01597-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000523029400012</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2385582916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c514t-72bdfa77d9005b4f107b89d26b9b12279033e2677a59a26b9afdcfa82235b8f83</originalsourceid><addsrcrecordid>eNqNkd-K1TAQxoso7rr6Al5IwBtBq8mkaZq9O5T1Dyx4o9clSZNj157kmKTIvoMP7dSuR_BCvAiZzPy-YSZfVT1l9DWjVL7JjLJG1pQpPELJur1XnbOGy1pKCfcx5g2rVQvirHqU8w2lTLYCHlZnnHVAgdHz6kf_RYf9FPbkqEtxKZDoSVkOMZGDTl9dymQKJDm7pORCITbOEV9Fz8TqYF1adRNWMjHOY4nkJe1duiUlnmTWXZLs0nIgR8GJDmUycZxcfkX6HQ6vMDWS_mr3uHrg9Zzdk7v7ovr89upT_76-_vjuQ7-7rq1gTaklmNFrKUdFqTCNZ1SaTo3QGmUYgFSUcwetlFoovWa1H63XHQAXpvMdv6hebH2PKX5bXC7DYcrWzbMOLi55AA68kYy3gOjzv9CbuKSA0yHVCdGBYi1SsFE2xZyT88MxTfh_twOjw-rVsHk1oFfDL6-GVfTsrvViDm48SX6bg0C3Ad-diT7baf3JE0ZxeeAUVIMRg34qaEQMfVxCQenL_5cizTc6IxHQvT9L_mP-n9NTv10</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2385582916</pqid></control><display><type>article</type><title>Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA</title><source>SpringerNature Journals</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><creator>Ushigome, Mitsunori ; Shimada, Hideaki ; Miura, Yasuyuki ; Yoshida, Kimihiko ; Kaneko, Tomonori ; Koda, Takamaru ; Nagashima, Yasuo ; Suzuki, Takayuki ; Kagami, Satoru ; Funahashi, Kimihiko</creator><creatorcontrib>Ushigome, Mitsunori ; Shimada, Hideaki ; Miura, Yasuyuki ; Yoshida, Kimihiko ; Kaneko, Tomonori ; Koda, Takamaru ; Nagashima, Yasuo ; Suzuki, Takayuki ; Kagami, Satoru ; Funahashi, Kimihiko</creatorcontrib><description>Background
The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.
Methods
A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.
Results
Although preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.
Conclusions
Postoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator.</description><identifier>ISSN: 1341-9625</identifier><identifier>EISSN: 1437-7772</identifier><identifier>DOI: 10.1007/s10147-019-01597-6</identifier><identifier>PMID: 31820210</identifier><language>eng</language><publisher>Singapore: Springer Singapore</publisher><subject>Antibodies ; Antigens ; Cancer ; Cancer Research ; Carbohydrates ; Carcinoembryonic antigen ; Colorectal cancer ; Colorectal carcinoma ; Immunoglobulins ; Life Sciences & Biomedicine ; Medical prognosis ; Medicine ; Medicine & Public Health ; Oncology ; Original Article ; p53 Protein ; Patients ; Science & Technology ; Surgery ; Surgical Oncology ; Tumor markers</subject><ispartof>International journal of clinical oncology, 2020-04, Vol.25 (4), p.622-632</ispartof><rights>Japan Society of Clinical Oncology 2019</rights><rights>Japan Society of Clinical Oncology 2019.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>24</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000523029400012</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c514t-72bdfa77d9005b4f107b89d26b9b12279033e2677a59a26b9afdcfa82235b8f83</citedby><cites>FETCH-LOGICAL-c514t-72bdfa77d9005b4f107b89d26b9b12279033e2677a59a26b9afdcfa82235b8f83</cites><orcidid>0000-0002-1990-8217</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10147-019-01597-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10147-019-01597-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,28253,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31820210$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ushigome, Mitsunori</creatorcontrib><creatorcontrib>Shimada, Hideaki</creatorcontrib><creatorcontrib>Miura, Yasuyuki</creatorcontrib><creatorcontrib>Yoshida, Kimihiko</creatorcontrib><creatorcontrib>Kaneko, Tomonori</creatorcontrib><creatorcontrib>Koda, Takamaru</creatorcontrib><creatorcontrib>Nagashima, Yasuo</creatorcontrib><creatorcontrib>Suzuki, Takayuki</creatorcontrib><creatorcontrib>Kagami, Satoru</creatorcontrib><creatorcontrib>Funahashi, Kimihiko</creatorcontrib><title>Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA</title><title>International journal of clinical oncology</title><addtitle>Int J Clin Oncol</addtitle><addtitle>INT J CLIN ONCOL</addtitle><addtitle>Int J Clin Oncol</addtitle><description>Background
The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.
Methods
A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.
Results
Although preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.
Conclusions
Postoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator.</description><subject>Antibodies</subject><subject>Antigens</subject><subject>Cancer</subject><subject>Cancer Research</subject><subject>Carbohydrates</subject><subject>Carcinoembryonic antigen</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>Immunoglobulins</subject><subject>Life Sciences & Biomedicine</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Oncology</subject><subject>Original Article</subject><subject>p53 Protein</subject><subject>Patients</subject><subject>Science & Technology</subject><subject>Surgery</subject><subject>Surgical Oncology</subject><subject>Tumor markers</subject><issn>1341-9625</issn><issn>1437-7772</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>AOWDO</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkd-K1TAQxoso7rr6Al5IwBtBq8mkaZq9O5T1Dyx4o9clSZNj157kmKTIvoMP7dSuR_BCvAiZzPy-YSZfVT1l9DWjVL7JjLJG1pQpPELJur1XnbOGy1pKCfcx5g2rVQvirHqU8w2lTLYCHlZnnHVAgdHz6kf_RYf9FPbkqEtxKZDoSVkOMZGDTl9dymQKJDm7pORCITbOEV9Fz8TqYF1adRNWMjHOY4nkJe1duiUlnmTWXZLs0nIgR8GJDmUycZxcfkX6HQ6vMDWS_mr3uHrg9Zzdk7v7ovr89upT_76-_vjuQ7-7rq1gTaklmNFrKUdFqTCNZ1SaTo3QGmUYgFSUcwetlFoovWa1H63XHQAXpvMdv6hebH2PKX5bXC7DYcrWzbMOLi55AA68kYy3gOjzv9CbuKSA0yHVCdGBYi1SsFE2xZyT88MxTfh_twOjw-rVsHk1oFfDL6-GVfTsrvViDm48SX6bg0C3Ad-diT7baf3JE0ZxeeAUVIMRg34qaEQMfVxCQenL_5cizTc6IxHQvT9L_mP-n9NTv10</recordid><startdate>20200401</startdate><enddate>20200401</enddate><creator>Ushigome, Mitsunori</creator><creator>Shimada, Hideaki</creator><creator>Miura, Yasuyuki</creator><creator>Yoshida, Kimihiko</creator><creator>Kaneko, Tomonori</creator><creator>Koda, Takamaru</creator><creator>Nagashima, Yasuo</creator><creator>Suzuki, Takayuki</creator><creator>Kagami, Satoru</creator><creator>Funahashi, Kimihiko</creator><general>Springer Singapore</general><general>Springer Nature</general><general>Springer Nature B.V</general><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1990-8217</orcidid></search><sort><creationdate>20200401</creationdate><title>Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA</title><author>Ushigome, Mitsunori ; Shimada, Hideaki ; Miura, Yasuyuki ; Yoshida, Kimihiko ; Kaneko, Tomonori ; Koda, Takamaru ; Nagashima, Yasuo ; Suzuki, Takayuki ; Kagami, Satoru ; Funahashi, Kimihiko</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c514t-72bdfa77d9005b4f107b89d26b9b12279033e2677a59a26b9afdcfa82235b8f83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Antibodies</topic><topic>Antigens</topic><topic>Cancer</topic><topic>Cancer Research</topic><topic>Carbohydrates</topic><topic>Carcinoembryonic antigen</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>Immunoglobulins</topic><topic>Life Sciences & Biomedicine</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Oncology</topic><topic>Original Article</topic><topic>p53 Protein</topic><topic>Patients</topic><topic>Science & Technology</topic><topic>Surgery</topic><topic>Surgical Oncology</topic><topic>Tumor markers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ushigome, Mitsunori</creatorcontrib><creatorcontrib>Shimada, Hideaki</creatorcontrib><creatorcontrib>Miura, Yasuyuki</creatorcontrib><creatorcontrib>Yoshida, Kimihiko</creatorcontrib><creatorcontrib>Kaneko, Tomonori</creatorcontrib><creatorcontrib>Koda, Takamaru</creatorcontrib><creatorcontrib>Nagashima, Yasuo</creatorcontrib><creatorcontrib>Suzuki, Takayuki</creatorcontrib><creatorcontrib>Kagami, Satoru</creatorcontrib><creatorcontrib>Funahashi, Kimihiko</creatorcontrib><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>International journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ushigome, Mitsunori</au><au>Shimada, Hideaki</au><au>Miura, Yasuyuki</au><au>Yoshida, Kimihiko</au><au>Kaneko, Tomonori</au><au>Koda, Takamaru</au><au>Nagashima, Yasuo</au><au>Suzuki, Takayuki</au><au>Kagami, Satoru</au><au>Funahashi, Kimihiko</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA</atitle><jtitle>International journal of clinical oncology</jtitle><stitle>Int J Clin Oncol</stitle><stitle>INT J CLIN ONCOL</stitle><addtitle>Int J Clin Oncol</addtitle><date>2020-04-01</date><risdate>2020</risdate><volume>25</volume><issue>4</issue><spage>622</spage><epage>632</epage><pages>622-632</pages><issn>1341-9625</issn><eissn>1437-7772</eissn><abstract>Background
The clinical impact of monitoring serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen in patients with colorectal cancer has not been fully evaluated.
Methods
A total of 420 surgically treated stage II/III colorectal cancer patients were retrospectively analyzed. Among them, 101 patients developed disease recurrence. The prognostic impact of preoperative and recurrence levels of serum p53 antibodies, carbohydrate antigen19-9, and carcinoembryonic antigen status was evaluated.
Results
Although preoperative carcinoembryonic antigen- and carbohydrate antigen19-9-positive status was significantly associated with recurrence, preoperative serum p53 antibody levels were not. Among two marker combinations, carcinoembryonic antigen + serum p53 antibodies showed the highest positive rate at recurrence. Although carcinoembryonic antigen and carbohydrate antigen19-9 frequently converted from preoperative-negative status to positive status at recurrence, serum p53 antibodies converted to positive status in only one patient. Carcinoembryonic antigen- and carbohydrate antigen19-9-positive status were significant prognostic factors for overall survival after recurrence, but the presence of serum p53 antibodies at recurrence was not.
Conclusions
Postoperative serum p53 antibody status should only be followed in patients with preoperative-positive status. Carcinoembryonic antigen and carbohydrate antigen19-9 should be followed even in preoperative-negative patients. Unlike carcinoembryonic antigen- and carbohydrate antigen19-9-positive status, serum p53 antibody-positive status as recurrence was not a poor prognostic indicator.</abstract><cop>Singapore</cop><pub>Springer Singapore</pub><pmid>31820210</pmid><doi>10.1007/s10147-019-01597-6</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1990-8217</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1341-9625 |
| ispartof | International journal of clinical oncology, 2020-04, Vol.25 (4), p.622-632 |
| issn | 1341-9625 1437-7772 |
| language | eng |
| recordid | cdi_webofscience_primary_000523029400012 |
| source | SpringerNature Journals; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /> |
| subjects | Antibodies Antigens Cancer Cancer Research Carbohydrates Carcinoembryonic antigen Colorectal cancer Colorectal carcinoma Immunoglobulins Life Sciences & Biomedicine Medical prognosis Medicine Medicine & Public Health Oncology Original Article p53 Protein Patients Science & Technology Surgery Surgical Oncology Tumor markers |
| title | Changing pattern of tumor markers in recurrent colorectal cancer patients before surgery to recurrence: serum p53 antibodies, CA19-9 and CEA |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T21%3A47%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Changing%20pattern%20of%20tumor%20markers%20in%20recurrent%20colorectal%20cancer%20patients%20before%20surgery%20to%20recurrence:%20serum%20p53%20antibodies,%20CA19-9%20and%20CEA&rft.jtitle=International%20journal%20of%20clinical%20oncology&rft.au=Ushigome,%20Mitsunori&rft.date=2020-04-01&rft.volume=25&rft.issue=4&rft.spage=622&rft.epage=632&rft.pages=622-632&rft.issn=1341-9625&rft.eissn=1437-7772&rft_id=info:doi/10.1007/s10147-019-01597-6&rft_dat=%3Cproquest_webof%3E2385582916%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2385582916&rft_id=info:pmid/31820210&rfr_iscdi=true |